Plain-English translation of NCT07496918 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether special devices that deliver 40Hz sensory stimulation—through flickering light, rhythmic sound, or gentle touch—can change how your brain works. Researchers believe this type of stimulation may help protect brain cells and support memory and attention, particularly for people at risk of cognitive decline.
Previous research suggests that Alzheimer's disease disrupts a specific pattern of brain activity called gamma oscillations. This study exists to see whether this non-invasive sensory stimulation can restore that brain activity and potentially prevent or slow cognitive problems before they start.
You likely qualify if…
You likely don't qualify if…
You would receive sessions of sensory stimulation using devices that deliver 40Hz light, sound, or other gentle stimulation. You would also complete brain imaging (MRI), memory and thinking tests, provide blood samples, and possibly answer questions about your health and gut microbiome. The study involves multiple visits to the research center over a defined period.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States
Testing effectiveness
Sponsor
Massachusetts Institute of Technology
Enrollment target
~150 participants
Started
February 2018
Primary completion
January 2027
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
gamma wave
Massachusetts Institute of Technology
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.